New cancer drug PM14 shows promise in early trial

NCT ID NCT05076396

Completed Disease control Sponsor: PharmaMar Source: ClinicalTrials.gov ↗

First seen May 15, 2026 · Last updated May 23, 2026 · Updated 2 times

Summary

This early-phase study tested a new drug called PM14 in 126 people with advanced solid tumors that had not responded to standard treatments. The main goals were to find the safest dose and to see if the drug could shrink tumors or slow their growth. The study is now complete, and results will help guide future research.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Clinica Universidad de Navarra

Madrid, Madrid, 28027, Spain
Gustave Roussy

Villejuif, París, 94805, France
Hospital General Universitario Gregorio Marañón

Madrid, Madrid, 28007, Spain
Hospital Universitari Vall d'Hebron

Barcelona, Catalonia, 08035, Spain
Hospital Universitario 12 de Octubre

Madrid, Madrid, 28041, Spain
Hospital Universitario Fundación Jiménez Díaz

Madrid, Madrid, 28040, Spain
Hospital Universitario Madrid Sanchinarro

Madrid, Madrid, 28050, Spain
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMOR